HRP20120561T1 - Metil fenilsulfonil piperazin il h benzimidazol kao hidroksitriptaminski ligand - Google Patents

Metil fenilsulfonil piperazin il h benzimidazol kao hidroksitriptaminski ligand Download PDF

Info

Publication number
HRP20120561T1
HRP20120561T1 HRP20120561AT HRP20120561T HRP20120561T1 HR P20120561 T1 HRP20120561 T1 HR P20120561T1 HR P20120561A T HRP20120561A T HR P20120561AT HR P20120561 T HRP20120561 T HR P20120561T HR P20120561 T1 HRP20120561 T1 HR P20120561T1
Authority
HR
Croatia
Prior art keywords
disorder
compound
disorders
disease
cognitive
Prior art date
Application number
HRP20120561AT
Other languages
English (en)
Croatian (hr)
Inventor
Simon@N@@Haydar
Patrick@M@@Andrae
Heedong@Yun
Albert@J@@Robichaud
Original Assignee
Wyeth@LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41404503&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20120561(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth@LLC filed Critical Wyeth@LLC
Publication of HRP20120561T1 publication Critical patent/HRP20120561T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/22—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms directly attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HRP20120561AT 2008-11-11 2009-11-10 Metil fenilsulfonil piperazin il h benzimidazol kao hidroksitriptaminski ligand HRP20120561T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11329608P 2008-11-11 2008-11-11
PCT/US2009/063816 WO2010056644A1 (en) 2008-11-11 2009-11-10 1- (ARYLSULFONYL) -4- (PI PERAZIN-I -YL) -IH-BENZ IMIDAZOLES AS δ-HYDROXYTRYPTAMINE- 6 LIGANDS

Publications (1)

Publication Number Publication Date
HRP20120561T1 true HRP20120561T1 (hr) 2012-07-31

Family

ID=41404503

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20120561AT HRP20120561T1 (hr) 2008-11-11 2009-11-10 Metil fenilsulfonil piperazin il h benzimidazol kao hidroksitriptaminski ligand

Country Status (41)

Country Link
US (1) US8063053B2 (enExample)
EP (1) EP2285784B1 (enExample)
JP (1) JP5087171B2 (enExample)
KR (1) KR101323417B1 (enExample)
CN (1) CN102209713B (enExample)
AP (1) AP2814A (enExample)
AR (1) AR074325A1 (enExample)
AU (1) AU2009314221B2 (enExample)
BR (1) BRPI0920682A2 (enExample)
CA (1) CA2740262C (enExample)
CL (1) CL2011001050A1 (enExample)
CO (1) CO6440548A2 (enExample)
CR (1) CR20110247A (enExample)
CU (1) CU24020B1 (enExample)
CY (1) CY1113025T1 (enExample)
DK (1) DK2285784T3 (enExample)
DO (1) DOP2011000130A (enExample)
EA (1) EA018369B1 (enExample)
EC (1) ECSP11011045A (enExample)
ES (1) ES2389694T3 (enExample)
GE (1) GEP20135805B (enExample)
HR (1) HRP20120561T1 (enExample)
IL (1) IL212213A0 (enExample)
MA (1) MA32788B1 (enExample)
ME (1) ME01129B (enExample)
MX (1) MX2011004996A (enExample)
MY (1) MY156324A (enExample)
NI (1) NI201100093A (enExample)
NZ (1) NZ592563A (enExample)
PE (1) PE20120026A1 (enExample)
PL (1) PL2285784T3 (enExample)
PT (1) PT2285784E (enExample)
RS (1) RS52381B (enExample)
SA (1) SA109300673B1 (enExample)
SI (1) SI2285784T1 (enExample)
SV (1) SV2011003902A (enExample)
TN (1) TN2011000203A1 (enExample)
TW (1) TWI481605B (enExample)
UA (1) UA100192C2 (enExample)
WO (1) WO2010056644A1 (enExample)
ZA (1) ZA201103283B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR051294A1 (es) * 2004-09-20 2007-01-03 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
CA2580857A1 (en) * 2004-09-20 2006-09-28 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
CN101084212A (zh) * 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为硬脂酰CoA去饱和酶介导剂的用途
AR051202A1 (es) * 2004-09-20 2006-12-27 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
CN104557726B (zh) * 2013-10-19 2019-05-24 广东东阳光药业有限公司 芳杂环类衍生物及其在药物上的应用
JP6515175B2 (ja) 2014-07-08 2019-05-15 サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． 芳香族ヘテロ環誘導体及びその医薬的適用
WO2017052394A1 (en) 2015-09-23 2017-03-30 Uniwersytet Jagielloński Imidazopyridine compounds and their use as 5-ht6 receptor ligands
EP3530651A1 (en) 2018-02-21 2019-08-28 Adamed sp. z o.o. Indole and benzimidazole derivatives as dual 5-ht2a and 5-ht6 receptor antagonists
WO2021021951A1 (en) 2019-07-29 2021-02-04 Vanderbilt University Wdr5-myc inhibitors
CA3179331A1 (en) * 2020-04-22 2021-10-28 Recurium Ip Holdings, Llc Preparation of an selective estrogen receptor degrader

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9700693A (es) * 1994-07-26 1997-04-30 Pfizer Derivados del 4-indol.
US5849759A (en) * 1995-12-08 1998-12-15 Berlex Laboratories, Inc. Naphthyl-substituted benzimidazole derivatives as anti-coagulants
DZ2376A1 (fr) 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
WO1999002502A2 (en) 1997-07-11 1999-01-21 Smithkline Beecham Plc Sulphonamide derivatives being 5-ht6 receptor antagonists and process for their preparation
GB9716656D0 (en) * 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
SI0930302T1 (en) 1998-01-16 2003-10-31 F. Hoffmann-La Roche Ag Benzosulfone derivatives
US6251893B1 (en) 1998-06-15 2001-06-26 Nps Allelix Corp. Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity
ATE231857T1 (de) * 1998-08-10 2003-02-15 Winston Pharmateuticals Llc Prodrugs für proton-pump-inhibitoren
GB9818916D0 (en) * 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
SE0002754D0 (sv) 2000-07-21 2000-07-21 Pharmacia & Upjohn Ab New pharmaceutical combination formulation and method of treatment with the combination
KR100823908B1 (ko) * 2000-10-20 2008-04-21 바이오비트럼 에이비(피유비엘) 2-, 3-, 4-, 또는 5-치환-ｎ1-(벤젠술포닐)인돌 및 이의치료 용도
SE0003810D0 (sv) * 2000-10-20 2000-10-20 Pharmacia Ab Novel compounds their use and preparations
US7034029B2 (en) * 2000-11-02 2006-04-25 Wyeth 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
EA006205B1 (ru) * 2000-11-02 2005-10-27 Уайт 1-арил- или 1-алкилсульфонилгетероциклилбензазолы в качестве лигандов 5-гидрокситриптамина-6
CN1321110C (zh) * 2001-06-15 2007-06-13 弗·哈夫曼-拉罗切有限公司 具有5－ht6受体亲和力的4－哌嗪基吲哚衍生物
DE60212841T2 (de) * 2001-06-15 2007-06-21 F. Hoffmann-La Roche Ag 4 piperazinylindolderivate mit affinität zum 5-ht6-rezeptor
WO2003026664A1 (en) 2001-09-26 2003-04-03 Bayer Corporation 2-phenylamino-4- (5-pyrazolylamino) -pyramidine derivatives as kinase inhibitors, in particular, src kinase inhibitors
US7122665B2 (en) 2002-10-15 2006-10-17 Synta Pharmaceuticals Corp. Heterocyclic compounds
CA2563895C (en) 2004-04-13 2012-10-16 Synta Pharmaceuticals Corp. Disalt inhibitors of il-12 production
EP1778242A4 (en) 2004-07-28 2010-10-20 Irm Llc COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROIDHORMONE NUCLEAR RECEPTORS
US7713954B2 (en) * 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders

Also Published As

Publication number Publication date
DOP2011000130A (es) 2017-04-30
TW201022247A (en) 2010-06-16
EA201100696A1 (ru) 2011-10-31
BRPI0920682A2 (pt) 2016-09-27
UA100192C2 (en) 2012-11-26
CN102209713B (zh) 2014-07-02
AU2009314221A1 (en) 2010-05-20
ECSP11011045A (es) 2011-06-30
CU24020B1 (es) 2014-07-30
CA2740262A1 (en) 2010-05-20
IL212213A0 (en) 2011-06-30
PL2285784T3 (pl) 2012-12-31
AP2814A (en) 2013-12-31
JP2012508275A (ja) 2012-04-05
SI2285784T1 (sl) 2012-08-31
MY156324A (en) 2016-02-15
CN102209713A (zh) 2011-10-05
GEP20135805B (en) 2013-04-10
MX2011004996A (es) 2011-05-25
DK2285784T3 (da) 2012-07-23
AP2011005664A0 (en) 2011-04-30
CL2011001050A1 (es) 2011-08-19
HK1158647A1 (en) 2012-07-20
CO6440548A2 (es) 2012-05-15
TN2011000203A1 (fr) 2012-12-17
PE20120026A1 (es) 2012-02-12
SA109300673B1 (ar) 2013-05-25
ZA201103283B (en) 2012-01-25
PT2285784E (pt) 2012-09-19
ES2389694T3 (es) 2012-10-30
TWI481605B (zh) 2015-04-21
MA32788B1 (fr) 2011-11-01
CY1113025T1 (el) 2016-04-13
WO2010056644A8 (en) 2010-11-18
KR101323417B1 (ko) 2013-10-29
CA2740262C (en) 2013-05-28
AR074325A1 (es) 2011-01-05
CR20110247A (es) 2011-06-24
RS52381B (sr) 2012-12-31
US8063053B2 (en) 2011-11-22
EP2285784A1 (en) 2011-02-23
AU2009314221B2 (en) 2012-08-30
KR20110075013A (ko) 2011-07-05
JP5087171B2 (ja) 2012-11-28
EP2285784B1 (en) 2012-07-04
CU20110101A7 (es) 2012-01-31
NI201100093A (es) 2011-10-31
EA018369B1 (ru) 2013-07-30
WO2010056644A1 (en) 2010-05-20
ME01129B (me) 2013-03-20
SV2011003902A (es) 2011-07-05
US20100120779A1 (en) 2010-05-13
NZ592563A (en) 2012-10-26

Similar Documents

Publication Publication Date Title
HRP20120561T1 (hr) Metil fenilsulfonil piperazin il h benzimidazol kao hidroksitriptaminski ligand
JP2014526435A5 (enExample)
MA32898B1 (fr) Modulateurs allosteriques positifs du recepteur m1 d'arylmethylbenzoquinazolinone
JP2012508275A5 (enExample)
BRPI0925343A2 (pt) Composto, composição farmacêutica, e, droga profilática ou terapêutica
CN109963854A (zh) 杂芳基并[4,3-c]嘧啶-5-胺类衍生物、其制备方法及其在医药上的应用
UY28940A1 (es) Derivados de quinazolina
CL2011002653A1 (es) Compuestos derivados de n-fenil-(piperazinil u homopiperazinil)-bencensulfonamida o bencensulfonil-fenil-(piperazina u homopiperazina), moduladores del receptor de serotonina 5-ht6; composicion farmaceutica; y su uso para el tratamiento para el tratamiento de enfermedades del sistema nervioso central, de adicion u obesidad.
BRPI0309303B8 (pt) compostos moduladores de receptores de 5ht2c, composição farmacêutica, e uso dos referidos compostos
NO20080317L (no) Substituerte tetrahydro-1H-Pyrido[4,3-B]Indoler som serotonin reseptor-agonister og antagonister
EA201890402A1 (ru) 5-htрецепторные агонисты и композиции и способы применения
NO20073051L (no) Tetralin- og indanderivater og deres anvedelse
MX2009005509A (es) 2-aminoquinolina como los antagonistas de los receptores 5-hidroxitriptamina 5a (5-ht5a).
NO20015413D0 (no) Anvendelse av dopamin-D3-reseptor-ligander for fremstilling av medikamenter for behandling av nyrefunksjonsforstyrrelser
TWI331919B (en) 5-ht1a receptor subtype agonist
ATE277927T1 (de) Aryl- und heteroaryl-kondensierte aminoalkyl- imidazol-derivate: selektive modulatoren der gabaa-rezeptoren
MX391442B (es) Agonistas y composiciones del receptor 5-ht2c y métodos de uso.
JP2015521642A5 (enExample)
MX2010009643A (es) Derivados de 2-aminoquinolina como antagonistas del receptor 5-hidroxitriptamina (5a).
NZ580801A (en) Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
SG11201910053YA (en) Trisubstituted pyrimidine compounds and compositions for the treatment of cancer, retinal disorders, and cardiomyopathies
JOP20210020A1 (ar) معدلات عطرية غير متجانسة لمستقبل nmda واستخداماتها
DE502004011551D1 (de) 1,3,4-substituierte pyrazole als 5-ht rezeptor-antagonisten zur behandlung von psychosen und neurologischen störungen
HRP20201152T1 (hr) Kondenzirani benzazepin za liječenje mucanja
SV2009002917A (es) Derivados de 3-alquilazetidina sustituidos con heterociclos